Clinical Trial Update: Dose Escalating Study for Amphinex-based PCI of Bleomycin. [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of Amphinex-based photochemical internalization with bleomycin has completed for skin cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Skin Cancer

Drugs mentioned

• Amphinex (amphiphilic photosensitizer)
• Bleomycin (bleomycin)

Snippet

Sponsor: PCI Biotech AS | Conditions: Cutaneous or Sub-cutaneous Malignancies | Phase 1 | Status: COMPLETED